查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1308601

2030 年體外膜氧合器 (ECMO) 市場預測：按產品、組件、模式、患者類型、應用和地區進行的全球分析

Extracorporeal Membrane Oxygenation Machine Market Forecasts to 2030 - Global Analysis By Product, Component, Modality, Patient Type, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球體外膜肺氧合 (ECMO) 市場規模將達到 6.0837 億美元，預測期內復合年增長率為 7.2%，預計到 2030 年2018年將達到9.8976億美元。

體外膜肺氧合（ECMO）是一種生命支持技術，用於患有嚴重末期疾病的患者，這些疾病會損害心臟和肺部的正常功能並阻止他們正常呼吸。. 除了幫助等待心臟或肺移植的患者外，該機制還提供心肺旁路支持。 根據患者的情況，ECMO 支持可能是短期的，從幾小時到幾天，也可能持續數週。

根據體外生命支持機構的數據，2016 年 1 月，大約 8,102 名兒童患有心髒病，需要 ECMO 治療。

市場動態：

驅動程序

肺移植中 ECMO 的使用增加

在預測期內，肺移植的需求不斷增加，特別是用於治療囊性纖維化、間質性肺病和慢性阻塞性肺病 (COPD) 等終末期肺病。 肺移植後原發性移植物功能障礙（PGD）是使用 ECMO 的最常見原因。 肺移植後 72 小時內發生的肺損傷稱為 PGD 綜合徵。 由於技術的重大進步，ECMO 作為移植後 PGD 患者的過渡性治療方式在各種研究中取得了有希望的結果。 由於全球肺部疾病患病率不斷上升，ECMO 的使用預計將進一步增加。

限制

ECMO產品成本高

ECMO 是一種昂貴的醫療程序。 除了系統相關費用外，還有醫院住宿和一次性配件等其他費用。 費用隨使用時間的長短而變化，但由於需要更多的醫務人員來照顧接受 ECMO 手術的患者，因此治療費用會增加。 接受 ECMO 支持的患者的住院時間通常為一到兩週，但根據患者病情的嚴重程度，住院時間可能會有所不同，甚至可能持續更長的時間。 因此，大多數患者無法承擔該手術的總費用。

機會

ECMO 提高生存率

患有潛在可逆性呼吸衰竭的患者，例如嚴重急性呼吸窘迫綜合徵（ADRS）、肺移植後原發性移植物衰竭以及肺損傷，應接受VV-ECMO治療。 接受VV-ECMO的呼吸衰竭患者存活率較高。 ECMO 設備也被應用於心臟，因為它們可以通過氧合支持功能失調的循環系統。 使用這些系統治療心力衰竭的心髒病患者的生存率有所提高。

威脅

缺乏熟練的專業人員

ECMO 是一種高度專業化且複雜的治療方法，需要對灌注師、重症監護師、護士和呼吸治療師進行培訓，使其具備有效操作和管理ECMO 設備的專業知識。需要一支訓練有素的醫療專業人員團隊。 然而，ECMO 療法的廣泛採用和使用受到具有 ECMO 特定知識和技能的訓練有素的專業人員數量有限的挑戰。 熟練的 ECMO 專業人員的短缺不僅影響了護理的提供，而且阻礙了 ECMO 項目的擴展和新的 ECMO 中心的建立。 如果沒有足夠數量的訓練有素的專業人員，醫療機構可□□能不願意投資 ECMO 設備或擴大 ECMO 服務，因為擔心人手不足和患者護理下降。

COVID-19 的影響：

COVID-19 大流行深刻改變了全球醫療格局，導致 2020 年體外膜肺氧合 (ECMO) 市場顯著高速增長。 這是由於病毒的廣泛傳播以及對這些機器提供循環支持和拯救生命的需求不斷增長。 COVID-19 患者治療效果的改善增加了醫院對體外膜氧合 (ECMO) 的採用，從而刺激了對體外膜氧合 (ECMO) 的需求。 為了應對不斷增長的需求，市場參與者在疫情期間見證了對其產品的需求增加。

預計泵領域在預測期內將是最大的領域：

由於其高成本和高使用率，泵領域也佔有相當大的市場份額。 ECMO 機器的泵通過氧合器幫助患者的血液充氧，然後再返回患者體內。 泵在ECMO治療中的廣泛使用以及多種類型泵（例如滾子泵、葉輪泵和離心泵）的出現極大地擴展了這一領域。 這些泵根據其要求用於各種 ECMO 程序，預計將在預測期內刺激該領域的市場擴張。

在預測期內，呼吸領域的複合年增長率最高：

在預測期內，呼吸領域將見證最高的市場複合年增長率。 由於目標疾病的快速傳播、早期診斷和醫學檢測的有限性以及體外膜肺氧合器市場的技術發展，該市場正在不斷擴大。 由於結核病、胸部惡性腫瘤、骨質疏鬆症、骨折和心血管疾病危險因素等呼吸系統疾病患病率的上升，診斷醫學成像也在不斷擴大，這將推動該領域的增長。

市場份額最高的地區：

北美在預測期內主導市場。 北美是體外膜肺氧合（ECMO）的重要市場，該地區有多家領先公司。 該地區市場的增長歸因於政府對優質醫療保健的支持、高購買力平價以及美國和加拿大慢性阻塞性肺病等疾病患病率的上升。 先進的醫療設施和優惠的報銷政策預計將增加住院人數，從而提高該地區的利用率。

複合年增長率最高的地區：

亞太市場預計在預測期內將以最快的速度增長。 老年人口的增加、可支配收入的增加、更先進技術的價格下降、目標疾病患病率的上升以及政府的支持措施（尤其是在日本）是亞太地區 ECMO 設備市場增長的主要推動力。 這些因素推動了該地區數字成像設備市場的發展，吸引了國外的合作和投資。 另一方面，亞太地區的市場擴張在一定程度上受到醫院預算低、設備成本高以及一些國家政府支出不足的限制。

主要進展：

  • 2022 年 5 月，微創科學公司收購 Hemovent GmbH，Hemovent GmbH 的 MOBYBOX ECMO 系統用於治療 COVID-19 患者，發表在領先的國際醫學期刊 - ASAIO Journal
  • 2022 年 11 月，LivaNova PLC 宣布 LifeSPARC 獲得 FDA 批准；
  • 2021年10月，微創醫療收購德國ECLS公司Hemovent GmbH，投資拓展德國業務
  • 2021 年 7 月，Xenios AG 的 Xenios 控制台和用於 ECMO 治療的患者套件獲得中國國家藥品監督管理局 (NMPA) 的批准

報告內容

  • 區域和國家層面的市場細分
  • 給新進入者的戰略建議
  • 涵蓋 2021 年、2022 年、2023 年、2026 年和 2030 年的市場數據
  • 市場趨勢
  • 根據市場預測提出關鍵業務領域的戰略建議
  • 競爭格局繪製主要共同趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和最新發展
  • 供應鏈趨勢映射最新技術趨勢

免費定制服務：

訂閱此報告的客戶將獲得以下免費自定義選項之一：

  • 公司簡介
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家/地區的市場估計/預測/複合年增長率（注：基於可行性檢查）
  • 競爭基準測試
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 執行摘要
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究來源
    • 二手研究來源
    • 先決條件

第三章市場趨勢分析

  • 驅動程序
  • 制約因素
  • 機會
  • 威脅
  • 產品分析
  • 使用情況分析
  • 新興市場
  • 新冠肺炎 (COVID-19) 的影響

第 4 章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間存在敵對關係

第五章全球體外膜氧合器 (ECMO) 市場：按產品

  • 便攜式設備
  • 固定設備
  • 軟件
  • 其他產品

第 6 章全球體外膜氧合 (ECMO) 市場：按組成部分

  • 泵
  • 制氧機
  • 控制器
  • 插管
  • 呼吸配件
  • 其他組件

第 7 章：全球體外膜氧合 (ECMO) 市場：按模式

  • 靜脈 - 靜脈
  • 靜脈-動脈
  • 動靜脈
  • 其他方式

第 8 章全球體外膜氧合 (ECMO) 市場：按患者類型劃分

  • 新生兒
  • 兒科
  • 成人

第 9 章全球體外膜氧合 (ECMO) 市場：按應用分類

  • 呼吸系統
  • 心
  • 體外心肺復蘇 (ECPR)
  • 心肺復蘇 (CPR)
  • 先天性心髒病
  • 橋接端口
  • 其他用途

第 10 章全球體外膜氧合 (ECMO) 市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東/非洲

第 11 章主要進展

  • 合同、合作夥伴關係、聯盟和合資企業
  • 收購與合併
  • 推出新產品
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • ABIOMED
  • EUROSETS
  • Getinge AB
  • LivaNova PLC
  • MAQUET Holding B.V. & Co. KG
  • Medos Medizintechnik AG
  • Medtronic
  • Microport Scientific Corporation
  • Nipro Medical Corporation
  • Sorin Group
  • Spectrum Medical
  • Terumo Cardiovascular Systems Corporation
  • Xenios AG
Product Code: SMRC23316

According to Stratistics MRC, the Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market is accounted for $608.37 million in 2023 and is expected to reach $989.76 million by 2030 growing at a CAGR of 7.2% during the forecast period. Extracorporeal membrane oxygenation is a type of life-supporting technology used for individuals with severe, terminal illnesses that impair their heart's or lungs' ability to function normally and keep them from breathing normally. In addition to helping those awaiting a heart or lung transplant, this mechanism offers heart-lung bypass support. Depending on the patient's medical state, ECMO machine support may be given for a short period of time-a few hours or days-or it may last for a few weeks.

According to the Extracorporeal Life Support Organization, in January 2016, around 8,102 children suffered from cardiac illness and required ECMO therapy.

Market Dynamics:

Driver:

Increasing use of ECMO in lung transplant procedures

The need for lung transplants has grown over the forecast period, particularly for the treatment of terminal lung conditions such as cystic fibrosis, Interstitial Lung Disease, and Chronic Obstructive Pulmonary Disease (COPD). Primary Graft Dysfunction (PGD) after lung transplantation is the most frequent cause for the use of ECMO. Lung damage that occurs within the first 72 hours after a lung transplant is known as PGD syndrome. The use of ECMO as a bridging method as a treatment for patients with PGD post-transplant has produced promising results in various studies thanks to considerable technological advancements. The use of ECMO is anticipated to increase further due to the rising prevalence of lung disorders worldwide.

Restraint:

High cost of ECMO products

ECMO is an expensive medical procedure. In addition to the expenditures related to the systems, there are other charges such as hospital lodging and extra disposable accessories. The cost of the treatment increases with the need for a large medical staff to care for the patient receiving an ECMO procedure, although the cost varies depending on how long it is used. The typical hospital stay for a patient receiving ECMO support is between one and two weeks, though it might vary depending on how serious the patient's condition is and last longer. The majority of patients cannot afford the procedure's higher overall cost as a result.

Opportunity:

Increasing survival rates with ECMO

Patients with potentially reversible respiratory failure, such as those with severe acute respiratory distress syndrome (ADRS), primary graft dysfunction following lung transplantation, and lung injury, should be treated with VV-ECMO. Patients with respiratory failure who receive VV-ECMO have a higher survival rate. Due to their capability to support failing circulatory systems with oxygenation functions, ECMO machines are also used in cardiac applications. The survival rates of cardiac patients who use these systems for heart failure are increased.

Threat:

Lack of skilled professionals

ECMO is a highly specialized and complex therapy that requires a team of trained healthcare professionals, including perfusionists, intensivists, nurses, and respiratory therapists, who possess the expertise to operate and manage ECMO machines effectively. However, the limited availability of trained professionals with ECMO-specific knowledge and skills poses challenges to the broader adoption and utilization of ECMO therapy. The lack of skilled professionals in ECMO not only affects the delivery of therapy but also impedes the expansion of ECMO programs and the establishment of new ECMO centers. Without a sufficient number of trained professionals, healthcare facilities may be hesitant to invest in ECMO machines or expand their ECMO services, fearing inadequate staffing and compromised patient care.

COVID-19 Impact::

The COVID-19 pandemic has significantly changed the landscape of healthcare practices worldwide and resulted in considerably high growth of the extracorporeal membrane oxygenation machine market in 2020. This is attributed to the vast spread of the virus and the increasing need for these machines to provide circulatory support and save lives. The improved machine outcome in COVID-19 patients led to increased adoption of these machines in hospitals, thereby fueling the demand for extracorporeal membrane oxygenation machines. Owing to the rise in demand, market players witnessed increased demand for their products during the pandemic.

The pumps segment is expected to be the largest during the forecast period:

The pumps segment also has a considerable market share owing to its high cost and usage. The ECMO machines' pumps assist in moving a patient's blood through artificial lungs for oxygenation before returning the blood to the patient. Due to the widespread use of pumps in ECMO treatments and the accessibility of many types of pumps, including roller, impeller, and centrifugal pumps, the segment has experienced significant expansion. According to their requirements, these pumps are employed in a variety of ECMO procedures, which will fuel the market expansion of this sector throughout the forecasted time.

The respiratory segment is expected to have the highest CAGR during the forecast period:

The respiratory segment has the highest CAGR in the market over the forecast period. The market is expanding due to the rapid spread of the target diseases, the limited availability of early diagnosis and medical testing, and technological developments in the Extracorporeal Membrane Oxygenation Machine Market. Diagnostic medical imaging is also expanding due to the rising incidence of respiratory diseases like tuberculosis, thorax malignant neoplasms, osteoporosis, broken bones, and CVD risk factors, which will propel the segment's growth.

Region with highest share:

North America dominated the market over the forecast period. North America is a significant market for Extracorporeal Membrane Oxygenation (ECMO) Machines, with several prominent players operating in the region. The growth of this market in the region can be attributed to the government support for quality healthcare, high purchasing power parity, and the increasing prevalence of diseases such as chronic obstructive pulmonary disease in the U.S. and Canada. The presence of sophisticated healthcare facilities and favorable reimbursement policies has led to an increased hospital admission rate which in turn is expected to boost the usage rates in this region.

Region with highest CAGR:

During the forecast period, the Asia Pacific market is anticipated to grow at the fastest rate. The rising geriatric population, especially in Japan, rising disposable incomes, making more advanced technologies affordable, the rising prevalence of target diseases, and supportive government initiatives are the main drivers of the ECMO machine market's growth in the Asia Pacific region. These elements propel the regional market for digital imaging equipment and draw in collaborations and investments from abroad. On the other hand, the expansion of the market in the Asia Pacific is being somewhat constrained by low hospital budgets, expensive equipment costs, and a lack of government expenditures in some nations.

Key players in the market

Some of the key players in Extracorporeal Membrane Oxygenation (ECMO) Machine Market include ABIOMED, EUROSETS, Getinge AB, LivaNova PLC, MAQUET Holding B.V. & Co. KG, Medos Medizintechnik AG, Medtronic, Microport Scientific Corporation, Nipro Medical Corporation, Sorin Group, Spectrum Medical, Terumo Cardiovascular Systems Corporation and Xenios AG.

Key Developments:

  • In May 2022, MicroPort Scientific Corporation acquired Hemovent GmbH and Hemovent GmbH's MOBYBOX ECMO System for the Treatment of COVID-19 Patients Published in Leading International Medical Journal-ASAIO Journal
  • In November 2022, LivaNova PLC announced the FDA clearance for LifeSPARC. The company received 510(k) approval for its next-generation advanced circulatory support system
  • In October 2021, MicroPort Scientific Corporation acquired German Extracorporeal life support (ECLS) company Hemovent GmbH and invested in expanding the company's German operations
  • In July 2021, Xenios AG received approval from the National Medical Products Administration (NMPA) in China for the Xenios Console and patient kits for ECMO therapy

Products Covered:

  • Portable Devices
  • Static Devices
  • Software
  • Other Products

Components Covered:

  • Pumps
  • Oxygenators
  • Controllers
  • Cannul a
  • Breathing Accessories
  • Other Components

Modalities Covered:

  • Veno-Venous
  • Veno-Arterials
  • Arterio-Venous
  • Other Modalities

Patient Types Covered:

  • Neonates
  • Pediatrics
  • Adults

Applications Covered:

  • Respiratory
  • Cardiac
  • Extracorporeal Cardiopulmonary Resuscitation (ECPR)
  • Cardiopulmonary Resuscitation (CPR)
  • Congenital Heart Defects
  • Bridge to Transplantation
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Product

  • 5.1 Introduction
  • 5.2 Portable Devices
  • 5.3 Static Devices
  • 5.4 Software
  • 5.5 Other Products

6 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Component

  • 6.1 Introduction
  • 6.2 Pumps
  • 6.3 Oxygenators
  • 6.4 Controllers
  • 6.5 Cannula
  • 6.6 Breathing Accessories
  • 6.7 Other Components

7 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Modality

  • 7.1 Introduction
  • 7.2 Veno-Venous
  • 7.3 Veno-Arterials
  • 7.4 Arterio-Venous
  • 7.5 Other Modalities

8 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Patient Type

  • 8.1 Introduction
  • 8.2 Neonates
  • 8.3 Pediatrics
  • 8.4 Adults

9 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Application

  • 9.1 Introduction
  • 9.2 Respiratory
  • 9.3 Cardiac
  • 9.4 Extracorporeal cardiopulmonary resuscitation (ECPR)
  • 9.5 Cardiopulmonary Resuscitation (CPR)
  • 9.6 Congenital Heart Defects
  • 9.7 Bridge to Transplantation
  • 9.8 Other Applications

10 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 ABIOMED
  • 12.2 EUROSETS
  • 12.3 Getinge AB
  • 12.4 LivaNova PLC
  • 12.5 MAQUET Holding B.V. & Co. KG
  • 12.6 Medos Medizintechnik AG
  • 12.7 Medtronic
  • 12.8 Microport Scientific Corporation
  • 12.9 Nipro Medical Corporation
  • 12.10 Sorin Group
  • 12.11 Spectrum Medical
  • 12.12 Terumo Cardiovascular Systems Corporation
  • 12.13 Xenios AG

List of Tables

  • Table 1 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Portable Devices (2021-2030) ($MN)
  • Table 4 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Static Devices (2021-2030) ($MN)
  • Table 5 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Software (2021-2030) ($MN)
  • Table 6 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Component (2021-2030) ($MN)
  • Table 8 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Pumps (2021-2030) ($MN)
  • Table 9 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Oxygenators (2021-2030) ($MN)
  • Table 10 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Controllers (2021-2030) ($MN)
  • Table 11 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cannula (2021-2030) ($MN)
  • Table 12 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Breathing Accessories (2021-2030) ($MN)
  • Table 13 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Components (2021-2030) ($MN)
  • Table 14 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Modality (2021-2030) ($MN)
  • Table 15 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Veno-Venous (2021-2030) ($MN)
  • Table 16 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Veno-Arterials (2021-2030) ($MN)
  • Table 17 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Arterio-Venous (2021-2030) ($MN)
  • Table 18 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Modalities (2021-2030) ($MN)
  • Table 19 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Patient Type (2021-2030) ($MN)
  • Table 20 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Neonates (2021-2030) ($MN)
  • Table 21 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Pediatrics (2021-2030) ($MN)
  • Table 22 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Adults (2021-2030) ($MN)
  • Table 23 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Respiratory (2021-2030) ($MN)
  • Table 25 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cardiac (2021-2030) ($MN)
  • Table 26 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Extracorporeal cardiopulmonary resuscitation (ECPR) (2021-2030) ($MN)
  • Table 27 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Cardiopulmonary Resuscitation (CPR) (2021-2030) ($MN)
  • Table 28 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Congenital Heart Defects (2021-2030) ($MN)
  • Table 29 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Bridge to Transplantation (2021-2030) ($MN)
  • Table 30 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.